Terence T Sio1, Pamela J Atherton2, Brandon J Birckhead3, David J Schwartz1, Jeff A Sloan2, Drew K Seisler2, James A Martenson1, Charles L Loprinzi4, Patricia C Griffin5, Roscoe F Morton6, Jon C Anders7, Thomas J Stoffel8, Robert E Haselow9, Rex B Mowat10, Michelle A Neben Wittich1, James D Bearden5, Robert C Miller11. 1. Department of Radiation Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. 3. Mayo Medical School, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. 4. Department of Oncology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA. 5. Upstate Carolina Community Clinical Oncology Program, Spartanburg, SC, USA. 6. Iowa Oncology Research Association Community Clinical Oncology Program, Des Moines, IA, USA. 7. Wichita Community Clinical Oncology Program, Wichita, KS, USA. 8. Cedar Rapids Oncology Project Community Clinic Oncology Program, Cedar Rapids, IA, USA. 9. Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN, USA. 10. Toledo Community Hospital Oncology Program CCOP, Toledo, OH, USA. 11. Department of Radiation Oncology, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA. miller.robert@mayo.edu.
Abstract
PURPOSE:Radiotherapy-related dermatological toxicities over time have not been well quantified. We examined during and immediately following radiation therapy skin toxicities over time in a randomized study of mometasone furoate vs placebo during breast radiotherapy. MATERIAL AND METHODS:Patients with breast cancer undergoing radiotherapy to the breast or chest wall were randomized. Symptoms related to skin toxicity were addressed weekly using provider-reported Common Terminology Criteria for Adverse Events (CTCAE v3.0) and 4 patient-reported outcomes (PRO) surveys. We applied repeated measures and risk analysis methodologies. RESULTS:One hundred seventy-six patients were enrolled. By CTCAE, significant differences favoring mometasone were detected over time in all toxicities except skin striae, atrophy, and infection. Statistically significant differences between arms at baseline but not over time occurred for all Linear Analog Self-Assessment. Statistically significant differences occurred for all symptoms in the temporal profile of symptoms as measured by PRO surveys (all P < .001). CONCLUSIONS: The use of longitudinal methods enhanced the ability of PRO tools to detect differences between study arms. Our results strengthened the conclusions of the original report that mometasone reduced acute skin toxicities. PRO surveys can accurately assess patients' experiences of symptom type and intensity over time and should be included in future clinical trials. For radiotherapy-related dermatological toxicity, we hypothesized that clinically significant differences over time, if any, can be found by repeated measures. We examined the acute skin toxicities in a randomized study of mometasone vs placebo during breast radiotherapy. For secondary end points, we showed that longitudinal methods enhanced the detection of differences between study arms and strengthened the conclusions from the original report. Frequent patient-reported outcome surveys over time should be included in future clinical trials.
RCT Entities:
PURPOSE: Radiotherapy-related dermatological toxicities over time have not been well quantified. We examined during and immediately following radiation therapy skin toxicities over time in a randomized study of mometasone furoate vs placebo during breast radiotherapy. MATERIAL AND METHODS:Patients with breast cancer undergoing radiotherapy to the breast or chest wall were randomized. Symptoms related to skin toxicity were addressed weekly using provider-reported Common Terminology Criteria for Adverse Events (CTCAE v3.0) and 4 patient-reported outcomes (PRO) surveys. We applied repeated measures and risk analysis methodologies. RESULTS: One hundred seventy-six patients were enrolled. By CTCAE, significant differences favoring mometasone were detected over time in all toxicities except skin striae, atrophy, and infection. Statistically significant differences between arms at baseline but not over time occurred for all Linear Analog Self-Assessment. Statistically significant differences occurred for all symptoms in the temporal profile of symptoms as measured by PRO surveys (all P < .001). CONCLUSIONS: The use of longitudinal methods enhanced the ability of PRO tools to detect differences between study arms. Our results strengthened the conclusions of the original report that mometasone reduced acute skin toxicities. PRO surveys can accurately assess patients' experiences of symptom type and intensity over time and should be included in future clinical trials. For radiotherapy-related dermatological toxicity, we hypothesized that clinically significant differences over time, if any, can be found by repeated measures. We examined the acute skin toxicities in a randomized study of mometasone vs placebo during breast radiotherapy. For secondary end points, we showed that longitudinal methods enhanced the detection of differences between study arms and strengthened the conclusions from the original report. Frequent patient-reported outcome surveys over time should be included in future clinical trials.
Entities:
Keywords:
Breast cancer; Clinical trials; Quality of life; Radiation; Radiation oncology
Authors: Walter J Scott; Mark S Allen; Gail Darling; Bryan Meyers; Paul A Decker; Joe B Putnam; Robert W McKenna; Rodney J Landrenau; David R Jones; Richard I Inculet; Richard A Malthaner Journal: J Thorac Cardiovasc Surg Date: 2010-02-20 Impact factor: 5.209
Authors: Pamela J Atherton; Kelli N Burger; Charles L Loprinzi; Michelle A Neben Wittich; Robert C Miller; Aminah Jatoi; Jeff A Sloan Journal: Support Care Cancer Date: 2011-09-16 Impact factor: 3.603
Authors: Michelle A Neben-Wittich; Pamela J Atherton; David J Schwartz; Jeff A Sloan; Patricia C Griffin; Richard L Deming; Jon C Anders; Charles L Loprinzi; Kelli N Burger; James A Martenson; Robert C Miller Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-01 Impact factor: 7.038
Authors: Eric Berthelet; Pauline T Truong; Karin Musso; Vickie Grant; Winkle Kwan; Veronika Moravan; Kelly Patterson; Ivo A Olivotto Journal: Am J Clin Oncol Date: 2004-12 Impact factor: 2.339
Authors: M Schmuth; M A Wimmer; S Hofer; A Sztankay; G Weinlich; D M Linder; P M Elias; P O Fritsch; E Fritsch Journal: Br J Dermatol Date: 2002-06 Impact factor: 9.302